 "Sun Pharma partners AstraZeneca to sell diabetes drug dapagliflozin in India")
Sun Pharmaceutical Industries Ltd and AstraZeneca Pharma India Limited have formed a partnership for the distribution of dapagliflozin, a type 2 diabetes medicine, in India. Dapagliflozin is AstraZeneca India’s diabetes medicine.
Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name Oxra. AstraZeneca India markets dapagliflozin under the brand name Forxiga and under the terms of the agreement, both companies will promote, market & distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights (IPRs) to dapagliflozin.
Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name Oxramet, following regulatory approval. AstraZeneca India is currently seeking approval from the Drug Controller General of India (DCGI) for the combination of dapagliflozin with metformin.
Sanjay Murdeshwar, managing director, AstraZeneca India, stated, “Dapagliflozin represents a significant advancement in the treatment of Type 2 diabetes and this agreement supports our strategy of working with a local partner to maximise the value from our innovative medicines in a key emerging market. It ensures a greater number of patients will have access to this important treatment option.”
Diabetes (all types) is estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide. By 2040, this will rise to 642 million and Type 2 is the most common form of diabetes.
As per IMS data, the size of the overall Indian anti-diabetes market is estimated at more than Rs 8400 crore (includes Type 1 & 2), growing at approximately 21 per cent Y-O-Y and highly fragmented with approximately 50 active players. However, the top 5 players (which includes Sun Pharma) cumulatively account for 50 percent of this market. Sun Pharma’s current diabetes portfolio comprises of over 40 specialty products with a market share of more than 8 per cent. It has the potential to significantly expand patient access to dapagliflozin and the combination of dapagliflozin with metformin treatment in India.
AstraZeneca India has a broad non-insulin portfolio addressing Type 2 diabetes and offers medicines in all the three novel and fast growing classes of Type 2 diabetes treatments: dipeptidyl peptidase-4 (DPP-4) inhibitors, SGLT2 inhibitor and glucagon-like peptide 1 (GLP-1) agonists in India.
Under the agreement, Sun Pharma will promote and distribute dapagliflozin under the brand name Oxra. AstraZeneca India markets dapagliflozin under the brand name Forxiga and under the terms of the agreement, both companies will promote, market & distribute dapagliflozin in India under different brand names. AstraZeneca will retain the intellectual property rights (IPRs) to dapagliflozin.
Sun Pharma will also gain the rights to promote and distribute the combination of dapagliflozin with metformin under the brand name Oxramet, following regulatory approval. AstraZeneca India is currently seeking approval from the Drug Controller General of India (DCGI) for the combination of dapagliflozin with metformin.
More From This Section
Abhay Gandhi, CEO - India Business, Sun Pharma, said, “This agreement for dapagliflozin further strengthens our partnership with AstraZeneca India. The addition of this innovative Type 2 diabetes treatment bolsters our diabetes portfolio. We believe the extended portfolio will further enhance our service capabilities to offer customers & patients innovative medicines at affordable prices. Through this partnership with AstraZeneca, access to dapagliflozin will be enhanced for doctors & Type 2 diabetes patients in India.”
Sanjay Murdeshwar, managing director, AstraZeneca India, stated, “Dapagliflozin represents a significant advancement in the treatment of Type 2 diabetes and this agreement supports our strategy of working with a local partner to maximise the value from our innovative medicines in a key emerging market. It ensures a greater number of patients will have access to this important treatment option.”
Diabetes (all types) is estimated to affect approximately 69.2 million people in India and more than 415 million people worldwide. By 2040, this will rise to 642 million and Type 2 is the most common form of diabetes.
As per IMS data, the size of the overall Indian anti-diabetes market is estimated at more than Rs 8400 crore (includes Type 1 & 2), growing at approximately 21 per cent Y-O-Y and highly fragmented with approximately 50 active players. However, the top 5 players (which includes Sun Pharma) cumulatively account for 50 percent of this market. Sun Pharma’s current diabetes portfolio comprises of over 40 specialty products with a market share of more than 8 per cent. It has the potential to significantly expand patient access to dapagliflozin and the combination of dapagliflozin with metformin treatment in India.
AstraZeneca India has a broad non-insulin portfolio addressing Type 2 diabetes and offers medicines in all the three novel and fast growing classes of Type 2 diabetes treatments: dipeptidyl peptidase-4 (DPP-4) inhibitors, SGLT2 inhibitor and glucagon-like peptide 1 (GLP-1) agonists in India.